IOVANCE BIOTHERAPEUTICS, INC. (formerly Lion Biotechnologies, Inc.) — Form 10-Q summary
Reporting period: Quarter ended March 31, 2013. The filing was signed October 22, 2013. The company was then a development-stage biopharmaceutical company developing autologous tumor-infiltrating lymphocyte therapies, including Cōntego for metastatic melanoma. It reported no operating revenue since inception.
Key financial results
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $434,913 | $2,250,133 |
| Research and development | $270,000 | $886,000 |
| Total costs and expenses | $704,913 | $3,136,133 |
| Interest expense | $341,616 | $88,472 |
| Net loss | $1,046,529 | $5,772,679 |
| Cash used in operating activities | $300,000 | $760,217 |
No revenue or profit margin was reported; margins are not meaningful for this pre-revenue company. The filing’s loss-per-share line displays $1.28 for 2013 and $7.39 for 2012 without parentheses, despite reporting net losses; the sign is therefore unclear in the presented text.
At March 31, 2013, total assets were $28,333, including $8,150 of current assets; cash was $0. Current liabilities were $12.31 million, total liabilities exceeded assets, and stockholders’ deficiency was $12.28 million. The MD&A separately reports a working-capital deficiency of $12.279 million. Notes totaling $6.781 million in principal were past due and in default or due on demand; accrued interest and penalties were $2.371 million. The company had no credit lines or other identified liquidity sources.
Changes and unusual items
- Net loss improved by about $4.73 million year over year, mainly because operating expenses and non-cash share-based compensation fell, R&D expense declined, and Q1 2012 had a $2.55 million derivative-liability loss that did not recur. Interest expense rose with higher debt balances and default rates.
- After quarter-end, the May 2013 restructuring converted debt and related securities into equity, extinguished approximately $9.27 million of liabilities, removed liens, and raised $1.25 million in equity proceeds. It issued 12.9 million shares in total, materially diluting existing holders and changing ownership. These were subsequent events, not Q1 results.
- In July 2013, the company acquired Lion Biotechnologies, Inc. for 1.34 million shares valued at approximately $6.7 million, with up to 1.35 million additional shares tied to milestones. In September, it changed its name to Lion Biotechnologies, Inc. and completed a 1-for-100 reverse split; share and per-share figures in the filing reflect the split retroactively.
- Research funding included a $250,000 quarterly CRADA commitment to NIH/NCI. The NIH license carried potential royalties and milestone payments, including up to $36.3 million across four indications if all benchmarks are achieved. The filing says an NIH amount was past due and the company was discussing a cure; disclosures give different amounts ($682,292 in the note and $616,000 in MD&A).
Outlook, risks, and controls
Management did not expect product-sale or licensing revenue in 2013 and expected losses to continue, potentially increasing as R&D activity grew. It said additional financing was required, had no committed funding source, and warned that failure to raise capital could force suspension or termination of development and threaten continued operations. The auditor had raised substantial doubt about the company’s ability to continue as a going concern. The filing also reports that senior debt was in default at quarter-end and that NIH could terminate the license following the payment default. No material pending litigation or material changes to previously disclosed risk factors were reported.
Management concluded disclosure controls were ineffective because of a material weakness involving insufficient segregation of accounting duties and expertise for complex transactions. No material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Post-quarter debt restructuring: exact debt extinguished, share issuance, dilution, and remaining liabilities and cash.
- Liquidity runway and financing commitments; the filing reports zero cash at quarter-end and no committed funding source.
- Status and amount of the overdue NIH obligation, and whether the license and CRADA remained in good standing.
- Loss-per-share presentation and the differing working-capital and NIH-payable figures in the filing.
- Remediation of the disclosed material weakness and the effects of the subsequent merger, reverse split, and ownership changes.